Is Bafna Pharmaceuticals the Best Stock in Its Sector? A Look at the Numbers
- September 23, 2026
- Posted by: Kunal Singla
- Category: Market
Bafna Pharmaceuticals CMP Rs 336 (23 Sep 2026). Market cap Rs 794 Cr. ROE 11.54%. P/E 101.98x versus Industry P/E 51.81x.
Quick Answer
Bafna Pharmaceuticals is one of the names investors compare when screening the Healthcare sector, built on a 11.54% return on equity and a P/E of 101.98x against an Industry P/E of 51.81x. Whether Bafna Pharmaceuticals is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.
Is Bafna Pharmaceuticals the best stock in its sector? The stock trades on the NSE at Rs 336 as of 23 September 2026, within its 52-week range of Rs 94.77 to Rs 336.50. Bafna Pharmaceuticals Ltd manufactures pharmaceutical formulations.
Bafna Pharmaceuticals sits in the Healthcare sector, and its 11.54% ROE and 101.98x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Bafna Pharmaceuticals
Bafna Pharmaceuticals Ltd manufactures pharmaceutical formulations. It manufactures pharmaceutical formulations, and the stock is currently trading at a fresh 52-week high, reflecting strong recent momentum that investors should weigh alongside the fundamentals. At a market capitalisation of Rs 794 Cr, it is tracked as part of the Healthcare sector on Univest.
Is Bafna Pharmaceuticals the Best Stock in Its Sector?
Bafna Pharmaceuticals makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 11.54% ROE with a 101.98x P/E against the sector’s 51.81x Industry P/E. Bafna Pharmaceuticals’ 101.98x P/E is well above the 51.81x Industry P/E despite an 11.54% ROE, a rich valuation that leans heavily on the stock’s recent momentum rather than current return ratios alone.
| Metric | Bafna Pharmaceuticals |
|---|---|
| CMP (NSE) | Rs 336.50 |
| 52-Week High / Low | Rs 336.50 / Rs 94.77 |
| Market Cap | Rs 794 Cr |
| P/E (TTM) vs Industry P/E | 101.98x vs 51.81x |
| P/B | 8.25 |
| ROE | 11.54% |
| EPS (TTM) | Rs 3.29 |
| Dividend Yield | 0.00% |
| Debt to Equity | 0.39 |
Compare Bafna Pharmaceuticals Against Other Healthcare Sector Stocks
How Bafna Pharmaceuticals Compares Against Its Healthcare Sector Peers
The table below sets Bafna Pharmaceuticals against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Bafna Pharmaceuticals | 794 | 101.98 | 11.54% | 0.39 |
| Alpa Laboratories | 128 | 31.43 | 8.06% | 0.01 |
| Anuh Pharma | 942 | 21.32 | 11.65% | 0.00 |
| Peer average (2 companies) | – | 26.38 | 9.86% | 0.01 |
Against this peer set, Bafna Pharmaceuticals’s 11.54% ROE is above the 9.86% peer average, and its P/E of 101.98x runs above the peer average of 26.38x. Bafna Pharmaceuticals’ 101.98x P/E is well above the 51.81x Industry P/E despite an 11.54% ROE, a rich valuation that leans heavily on the stock’s recent momentum rather than current return ratios alone.
What Makes Bafna Pharmaceuticals Worth Watching in Healthcare
- Solid ROE: An 11.54% ROE is a reasonable figure for a pharmaceutical formulations manufacturer.
- Moderate leverage: A debt to equity ratio of 0.39 is manageable for a formulations manufacturer.
- Trading at a fresh 52-week high: The stock is currently at its 52-week high, reflecting strong recent momentum that investors should weigh alongside the fundamentals.
Bafna Pharmaceuticals Valuation: Is It Justified?
Bafna Pharmaceuticals’ 101.98x P/E is well above the 51.81x Industry P/E despite an 11.54% ROE, a rich valuation that leans heavily on the stock’s recent momentum rather than current return ratios alone. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is Arvind Fashions the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Bafna Pharmaceuticals and other Healthcare sector stocks.
How to Track Bafna Pharmaceuticals Before You Invest
Before deciding whether Bafna Pharmaceuticals deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.
- Open the Univest Screener and search for Bafna Pharmaceuticals to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
- Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Bafna Pharmaceuticals earns a place in the best stock in its sector conversation on the strength of a 11.54% ROE and a P/E of 101.98x against a 51.81x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Bafna Pharmaceuticals the best stock in its sector?
Ans. Bafna Pharmaceuticals has a 11.54% ROE and trades at 101.98x P/E against a 51.81x Industry P/E, and compares above the peer average ROE of 9.86% in this article’s named comparison, so the answer depends on what an investor is prioritising.
What is the current share price of Bafna Pharmaceuticals?
Ans. Bafna Pharmaceuticals was trading at Rs 336.50 on the NSE as of 23 September 2026, within its 52-week range of Rs 94.77 to Rs 336.50.
What sector does Bafna Pharmaceuticals belong to?
Ans. Bafna Pharmaceuticals is classified under the Healthcare sector on Univest.
How does Bafna Pharmaceuticals compare to its sector peers on P/E?
Ans. Bafna Pharmaceuticals’s P/E of 101.98x is above the 26.38x average of the 2 named peers compared in this article.
What is Bafna Pharmaceuticals’s return on equity?
Ans. Bafna Pharmaceuticals reported a return on equity of 11.54%, which is above the 9.86% average of its named peers in this comparison.
Should I invest in Bafna Pharmaceuticals based on its sector position?
Ans. Bafna Pharmaceuticals’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.
